Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     

  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     

  • Bitcoin GBP

    51,781.33
    +1,652.09 (+3.30%)
     

  • CMC Crypto 200

    1,371.97
    +59.34 (+4.52%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

Has Innoviva (INVA) Outpaced Other Medical Stocks This Year?

Zacks Equity Research
·2-min read

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Innoviva (INVA) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.

Innoviva is a member of the Medical sector. This group includes 887 individual stocks and currently holds a Zacks Sector Rank of #1. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. INVA is currently sporting a Zacks Rank of #1 (Strong Buy).

The Zacks Consensus Estimate for INVA's full-year earnings has moved 13.46% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

ADVERTISEMENT

According to our latest data, INVA has moved about 7.77% on a year-to-date basis. At the same time, Medical stocks have lost an average of 0.23%. As we can see, Innoviva is performing better than its sector in the calendar year.

Looking more specifically, INVA belongs to the Large Cap Pharmaceuticals industry, which includes 15 individual stocks and currently sits at #22 in the Zacks Industry Rank. On average, stocks in this group have lost 0.10% this year, meaning that INVA is performing better in terms of year-to-date returns.

Going forward, investors interested in Medical stocks should continue to pay close attention to INVA as it looks to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Innoviva, Inc. (INVA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research